Covered is a method of purifying or extracting a type of stem cells from the fetal neural crest. This population of stem cells expresses low-affinity nerve growth factor receptor (LNGFR) and nestin and can differentiate into various cells of the neural lineage.
This patent covers differentiated teratocarinoma cells as a source of neurons. The concepts and subject matter of this patent actually was used in clinical trials for stroke.
This patent provides gelatin-based compounds that allow for the preservation of various cells, including stem cells of the hematopoietic lineage.
This patent covers genetic transfection of stem cells that give rise to neutrophils. Transfection of this cell population may be performed to enhance their ability to proliferate, or may be performed to endow them with increased antibacterial activities.
This patent is useful for parties seeking to purify hepatic progenitor cells, or hepatic stem cells. The patent has one independent claim that essentially teaches how to "negatively deplete" a single cell suspension of hepatocytes for all cells except hepatic stem cells. The patent also claims the marker OC3 as expressed on hepatic stem cells. A...
This patent provides the genes that are expressed in various neuronal cells and stem cells. These genes are useful for identifying markers of stem cells that can be used for their extraction and isolation. Additionally, knowledge of these genes may enable drug discovery and target identification for ways of expanding and/or differentiating neural stem cells.
As part of Osiris's territorial stake on the mesenchymal stem cell area, this patent covers antibodies that are publically available from ATCC, that specifically recognize mesenchymal stem cells.
This patent teaches ways of purifying hematopoietic stem cells based on their expression of the marker c-kit. This marker is the receptor for the cytokine stem cell factor that was developed by Amgen.
This patent teaches that cells expressing flk-1 on their surface may be stem cells. It specifically provides methods of using flk-1, alone, or in combination with other markers for the purification of stem cells.
This patent teaches that stem cells have an active efflux mechanism similar to the way that cancer cells have an efflux mechanism that makes them drug resistant. The only question about this patent is whether it also covers stem cells that are already identified using other markers. For example, it is very likely that the stem cells, at least hematopoietic stem cells that possess the efflux...